Compare SSTI & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSTI | WHWK |
|---|---|---|
| Founded | 1996 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.3M | 95.2M |
| IPO Year | 2017 | N/A |
| Metric | SSTI | WHWK |
|---|---|---|
| Price | $6.59 | $2.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | ★ 205.8K | 203.1K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $102,749,000.00 | $14,384,000.00 |
| Revenue This Year | $4.97 | N/A |
| Revenue Next Year | $10.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.78 | $1.39 |
| 52 Week High | $19.43 | $3.81 |
| Indicator | SSTI | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 37.41 | 62.77 |
| Support Level | $5.78 | $2.10 |
| Resistance Level | $6.35 | $2.36 |
| Average True Range (ATR) | 0.45 | 0.16 |
| MACD | 0.15 | 0.03 |
| Stochastic Oscillator | 59.83 | 100.00 |
SoundThinking Inc is a public safety technology company that combines transformative solutions and strategic advisory services for law enforcement and civic leadership. Its flagship SafetySmart platform includes ShotSpotter, the acoustic gunshot detection system, CrimeTracer, the foremost law enforcement search engine, CaseBuilder, a one-stop investigation management system, and ResourceRouter, software that directs patrol and community anti-violence resources to help maximize their impact.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.